Kisqali is a prescription drug used for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. To buy Kisqali 600 mg or to know its price contact 3S Corporation.
Manufacturer : Novartis Pharmaceuticals Corporation
Strengths available : 600 mg
Form : Tablets
Dosage : The recommended dose of kisqali is 600 mg (three 200 mg film-coated tablets) taken orally, once daily for 21 consecutive days followed by 7 days off treatment resulting in a complete cycle of 28 days. Kisqali can be taken with or without food.
Storage : Store at 20°C to 25°C
Is the medicine FDA approved : Yes
Date of Approval : March 13, 2017
Common side effects are Black, tarry, stools, bladder pain, bloating or swelling of the face, arms, hands, lower legs, or feet, bloody or cloudy urine, chills, cough, difficult or labored ,breathing difficult, burning, or painful urination, fever, frequent urge to urinate, lower back or side pain, pale skin, rapid weight gain, sore throat, tightness in the chest, tingling of the hands or feet, troubled breathing with exertion, ulcers, sores, or white spots in the mouth, unusual bleeding or bruising, unusual tiredness or weakness, unusual weight gain or loss.
Pack of 63 film-coated tablets